Table 3.
Medication in JDM patients total, < 20y and ≥ 20y
| Medication | Patients (n = 59) | Patients < 20 y (n = 28) | Patients ≥ 20 y (n = 31) | p-values |
|---|---|---|---|---|
| Prednisolone or DMARD at FU, n | 17 (28.8) | 13 (46.4) | 4 (12.9) | 0.004 |
| Prednisolone at FU (yes/no), n | 10 (16.9) | 7 (12.5) | 3 (4.8) | 0.13 |
| Methotrexat at FU, n | 10 (8.5) | 9 (16.1) | 1 (1.6) | 0.01 |
| Prednisolone during disease course, n | 51 (86.4) | 26 (92.9) | 25 (80.6) | 0.17 |
| Methotrexat during disease course, n | 30 (50.8) | 18 (64.3) | 12 (38.7) | 0.05 |
| Prednisolone medication time, months | 31 (14.0–57.0) | 24.5 (13.3–35.0) | 48.0 (16.0–85.0) | 0.05 |
| Cumulative prednisolone total, g | 7.90 (30.00–79.23) | 6.14 (0.00–16.23) | 9.68 (0.00–79.23) | 0.03 |
| Cumulative prednisolone 6 m after diagnosisa, g (n = 58/28/31) | 2.76 (0.00–6.65) | 2.89 (0.00–6.38) | 2.61 (0.00–6.65) | 0.60 |
| Cumulative prednisolone 2 y after diagnosis, g | 4.81 (0.00–0-16.50) | 4.26 (0.00–9.80) | 6.75 (0.00–16.49) | 0.19 |
| Cumulative prednisolone 6.5 y after diagnosis, g | 7.35 (0.00–28.39) | 6.14 (0.00–12.64) | 9.43 (0.00–28.40) | 0.18 |
| Time from last prednisolone dose to FU, months | 67.0 (0–162.0) | 42.7 (0–67.8) | 145.0 (0–253.0) | 0.002 |
FU follow up, a n = 56, values are n (%) and median (range). p-values when comparing JDM <20y and JDM ≥20y